FDA has a long history of using what we currently call real-world data (RWD) and real-world evidence (RWE) to monitor and evaluate the postmarket safety of […]

Summary Company Announcement Date: June 06, 2025 FDA Publish Date: June 06, 2025 Product Type: Drugs Reason for Announcement: Recall Reason Description Microbial contamination Company Name: […]

“Q&A with FDA” provides engaging conversation and discussion about the latest regulatory topics. In this podcast series, FDA’s Division of Drug Information will answer some of […]

Docket Number: FDA-2022-D-3054 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research, Office of Regulatory Policy Center for Biologics Evaluation and Research The Food […]

Docket Number: FDA-2022-D-3054 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research, Office of Regulatory Policy Center for Biologics Evaluation and Research The Food […]

Summary Company Announcement Date: June 02, 2025 FDA Publish Date: June 04, 2025 Product Type: Drugs Reason for Announcement: Recall Reason Description Microbial contamination Company Name: […]

INNOVATION   PREDICTABILITY   ACCESSFDA’s Center for Drug Evaluation and ResearchJanuary 2023 Table of Contents Director’s Message Patrizia Cavazzoni, M.D., Director, Center for Drug Evaluation and Research Welcome […]

Docket Number: FDA-2025-D-1358 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research The Food and Drug Administration (FDA or Agency) is announcing the availability […]

On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC). The FDA previously […]